European Neuropsychopharmacology (v.16, #S1)

The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results by O.D. Howes; S.A. Montgomery; M. Asselin; R.M. Murray; P.K. McGuire; P. Grasby (S65-S66).

The role of medial septal NMDA receptors in behavioral functions of the hippocampus in the rat by E. Elvander Tottie; T. Eriksson; B. Johansson; J. Sandin; S.O. Ögren (S62-S63).

Behavioral effects of SR 58611A, a beta-3 agonist, on experimental models of mild stress by G.M. Leggio; V. Micale; D. Consoli; C. Mazzola; F. Drago (S61-S62).

Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in a rat model of depression by G. Capone; S. Alboni; C. Benatti; F. Tascedda; J.M.C. Blom; J. Mendlewicz; N. Brunello (S61).

Changes in benzodiazepine receptor binding in Dutch veterans with posttraumatic stress disorder by E. Geuze; B.N.M. van Berckel; R. Boellaard; B.D. Windhorst; G. Luurtsema; A.A. Lammertsma; E. Vermetten; H.G.M. Westenberg (S66-S67).

Association study of a functional cathechol-O-methyltransferase polymorphism and cognitive remediation in schizophrenia by M. Bosia; R. Cavallaro; S. Anselmetti; M. Bechi; F. Cocchi; S. Poletti; E. Marino (S67-S68).

Influence of serotonin transporter promoter polymorphism on brain activation during a moral valence decision task by D. Radaelli; A. Bernasconi; F. Benedetti; V. Blasi; C. Colombo; A. Falini; G. Scotti; E. Smeraldi (S70-S71).

Influence of brain activity at the baseline on antidepressant response to chronotherapeutic treatments: a fMRI study by S. Dallaspezia; F. Benedetti; A. Bernasconi; V. Blasi; C. Colombo; A. Falini; D. Radaelli; G. Scotti; E. Smeraldi (S70).

Changes in brain glutamate correlate with antidepressant response to total sleep deprivation: a 3 T 1H-MRS study by A. Bernasconi; G. Calabrese; F. Benedetti; D. Radaelli; S. Dallaspezia; A. Falini; C. Colombo; M. Cadioli; G. Scotti; E. Smeraldi (S69).

Cannabis use increases body mass index in patients with psychosis by V. Mondelli; M. Di Forti; F. Saeedzadeh-Sardahaee; A. Butt; A. Miorelli; A. Mule; R. Gafoor; P. Dazzan; R.M. Murray; C.M. Pariante (S68-S69).

Prenatal stress in rats attenuates hippocampal long-term potentiation and induces deficits in synaptic plasticity by S. Salomon; Y. Nachum-Biala; Y. Bogush; M. Lineal; H. Matzner; R. Yaka; M. Weinstock (S52).

Cannabinoid modulation of impulsivity in rats: a novel pharmacotherapeutic approach for inhibitory control deficits? by T. Pattij; M.C.W. Janssen; I. Schepers; G. Gonzalez Cuevas; A.N.M. Schoffelmeer (S49-S50).

Semax effects on rat behavior changes induced by chronic restraint stress by D. Vilenskiy; D. Ivanova; N. Levitskaya; L. Andreeva; A. Kamensky; N. Myasoedov (S53).

The anxiolytic effect of CRF in rat brain frontal cortex is prevented by CRF1&2 receptor antagonists by B. Zieba; T. Uchacz; H. Domin; P. Branski; M. Smialowska; A. Pilc (S53-S54).

Effects of nicotinic receptor blockade on nicotine conditioned behaviors in rats by E.S. Zakharova; O.A. Dravolina; W. Danysz; E.E. Zvartau; A.Y. Bespalov (S57).

Abnormal social cognitive processing in 47, XXY men: implications for the study of schizophrenia by S. van Rijn; H. Swaab; A. Aleman; T. Jellema; R.S. Kahn (S54-S55).

Long term outcome of drug-resistant bipolar depression: a 9 months prospective follow-up after chronotherapeutics by A. Pontiggia; F. Benedetti; B. Barbini; M. Cigala Fulgosi; C. Colombo; S. Dallaspezia; E. Smeraldi (S72-S73).

Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opioid receptor agonist by R. Vergura; G. Balboni; B. Spagnolo; E.C. Gavioli; D.G. Lambert; J. McDonald; C. Trapella; D. Regoli; S. Salvadori; G. Calo (S89-S90).

Possible genetic implications of the endocannabinoid system in anxiety disorders versus depressive disorders by A. Erhardt; P.G. Unschuld; S. Lucae; M. Ising; D. Salyakina; B. Pütz; B. Müller-Myhsok; E.B. Binder; F. Holsboer; M.E. Keck (S88).

Molecular dissection of the role of GABAB1 receptor isoforms 1a and 1b in anxiety-related behaviour by L.H. Jacobson; H.C. Neijt; B. Bettler; K. Kaupmann; J.F. Cryan (S91-S92).

Author index (S95-S98).

Keyword index (S99-S100).

Anxiogenic drug treatment increases serotonin metabolism in specific anxiety-related forebrain circuits by A.K. Evans; J.K. Abrams; J.A. Bouwknecht; D.M. Knight; C.A. Lowry; A. Shekhar (S93).

New drug targets for anxiety by J. Hagan (S85).

Childhood adversity is associated with reduced central dopamine sensitivity later in life by A.F.A. Schellekens; R.J. Verkes; B. Ellenbroek; C.A.J. de Jong; J.K. Buitelaar (S77).

Basal ganglia in schizophrenia: a diffusion weighted imaging study by A. Versace; M. Tansella; N. Andreone; R. Cerini; L. Pellizza; G. Rambaldelli; G. Marrella; P. Brambilla (S76).

SNPs in FKBP5 determine a novel subtype of depression characterized by rapid response to antidepressant treatment by E.B. Binder; S. Lucae; D. Salyakina; P. Lichtner; T. Meitinger; B. Bondy; G. Wochnik; T. Rein; F. Holsboer; B. Müller-Myhsok (S75).

Divalproex sodium vs. placebo for the treatment of child and adolescent autism by E. Anagnostou; L. Soorya; E. Swanson; J. Rusoff; W. Chaplin; S. Wasserman; E. Hollander (S74-S75).

Progressive brain volume changes in first-episode psychosis: a five-year follow-up study by M. Rais; W. Cahn; N.E.M. van Haren; H.E. Hulshoff Pol; E. Caspers; H.G. Schnack; R.S. Kahn (S78-S79).

Single or low dose of ecstasy, is it safe? A prospective study on neurotoxicity of ecstasy in new ecstasy users by M.M.L. de Win; G. Jager; L. Reneman; C. Lavini; W. van den Brink; G.J. den Heeten (S79-S80).

Predictive factors of resistance to antidepressants in bipolar depression: results from a European multicentre study by P. Oswald; D. Souery; S. Kasper; Y. Lecrubier; S.A. Montgomery; J. Zohar; J. Mendlewicz (S83).

An open-label trial of escitalopram in the treatment of impulsive-compulsive internet usage disorder by B. Dell' Osso; A.C. Altamura; S.J. Hadley; B.R. Baker; E. Hollander (S82-S83).

The effects of exertion and high levels of lactate in a 35% CO2 challenge in patients with panic disorder by G. Esquivel; C. Berlanga-Cisneros; C. Lara-Muñoz; E. Griez (S81-S82).

Specific effects of ecstasy on memory: a new approach to investigate neurotoxic effects in poly-substance ecstasy users by G. Jager; M.M.L. de Win; I. van der Tweel; R.S. Kahn; J.M. van Ree; W. van den Brink; N.F. Ramsey (S80-S81).

Lithium inhibits stimulated striatal abundant adenylyl cyclase type V by L. Mann; G. Shaltiel; E. Heldman; R.H. Belmaker; G. Agam (S14).

Lithium effects on basal and stimulated CREB phosphorylation in SH-SY5Y cells: a bimodal action on CaMKIV and Erk1/2 by D. Tardito; I. Pelizzoni; A. Soncin; J. Kasahara; G. Racagni; M. Popoli (S13-S14).

Polymorphic variants in the transcriptional control region of TPH2 are preferentially transmitted in ADHD by T. Renner; S. Walitza; A. Dempfle; K. Konrad; Ch. Wewetzer; A. Halbach; B. Herpertz-Dahlmann; H. Remschmidt; J. Smidt; M. Linder; L. Flierl; U. Knölker; S. Friedel; H. Schäfer; C. Gross; J. Hebebrand; A. Warnke; K.P. Lesch (S21-S22).

Functional proteomic analysis of an animal model of depression combining genetic vulnerability and environmental stress by A. Mallei; R. Giambelli; V.S. Barbiero; M. Maglione; A.A. Mathè; A. El Khoury; L. Carboni; E. Domenici; G. Racagni; M. Popoli (S20-S21).

Biomarker discovery in cerebrospinal fluid of depressed patients by C. Ditzen; N. Tang; A. Jacob; M. Uhr; C. Miller; C.W. Turck (S19-S20).

Vagus nerve stimulation increases neurotrophins gene expression and alters cell proliferation in the rat hippocampus by P. Follesa; F. Biggio; S. Caria; G. Gorini; F. Marrosu; G. Biggio (S18-S19).

Differential accumulation of cortisol and corticosterone in the murine brain by B. Mason; C.M. Pariante; L. Sanderson; S.A. Thomas (S10-S11).

Fluorescence in vitro studies of human dopamine d1 and d2 receptor proteins interaction by A. Faron-Gorecka; J. Andrecka; M. Dziedzicka-Wasylewska; Z. Wasylewski (S4-S5).

ERK 1/2 and CaMKII: two novel targets for antipsychotic therapy? by A. Frasca; F. Fumagalli; G. Racagni; M.A. Riva (S5).

Autism candidate genes in cytogenetic regions of interest identified with a gene interaction network by W. Staal; L. Franke; J.A.S. Vorstman; H. van Engeland; C. Wijminga (S6).

Association analysis of limbic system-associated membrane protein gene polymorphisms in mood and anxiety disorders by K. Koido; S. Kõks; A. Must; A. Reimets; E. Maron; J. Shlik; V. Vasar; E. Vasar (S9).

Decreased D-serine levels in CSF of schizophrenia patients by S. Amar; I. Bendikov; C. Nadri; R.A. Panizzutti; J. De Miranda; H. Wolosker; G. Agam (S10).

Correlations between serum orexins A and B and ghrelin and BMI in anorexia nervosa by M. Janas-Kozik; I. Krupka-Matuszczyk; M. Krzystanek (S7-S8).

Combination of deferoxamine and lamotrigine in a rat model of hypoxic-ischemic brain damage by G. Papazisis; D. Kouvelas; K. Kallaras; A. Kaiki-Astara; O. Guiba-Tziampiri (S6-S7).

Chronic desipramine treatment suppresses cortical BDNF expression and ERK phosphorylation by J.B. O' Sullivan; L. Coleman; N.T. Boyle; T.J. Connor (S23).

Explaining birth seasonality in fall-winter depression: idiosyncratic procreational patterns in the patients' parents by E. Pjrek; D. Winkler; A. Konstantinidis; J. Stastny; M. Willeit; N. Praschak-Rieder; S. Kasper (S39).

Behavioral and biochemical effects of single dose of desipramine are time-dependent by M. Kusmider; A. Faron-Gorecka; M. Dziedzicka-Wasylewska (S42-S43).

Clozapine application in prefrontal cortex blocks the effects of systemic MK-801 on extracellular 5-HT and glutamate by X. López-Gil; Z. Babot; M. Amargós-Bosch; C. Suñol; F. Artigas; A. Adell (S46-S47).

Effect of antidepressant drugs in mice lacking the norepinephrine transporter by E. Drozdowska; A. Faron-Gorecka; M. Kusmider; Z. Rogoz; J. Siwanowicz; M.G. Caron; H. Bonisch; M. Dziedzicka-Wasylewska (S44).

Genetic association data from GENDEP, a multicentre European study by P. Huezo-Diaz; M. Nash; F. Hoda; R. Williamson; P. McGuffin; I. Craig; K.J. Aitchison (S35-S36).

Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines by L. Scott; S. Zelenin; S. Malmersjö; J.M. Kowalewski; E. Zettergren-Markus; A.C. Nairn; P. Greengard; H. Brismar; A. Aperia (S34-S35).

Glucocorticoid sensitivity in whole blood cells from healthy volunteers: effect of antidepressants by L. Oarvalho; M.F. Juruena; A. Papadopoulos; L. Poon; R. Kerwin; C.M. Pariante (S24-S25).

CYP2D6 variants and ecstasy-induced changes in neurohypophysial hormones by E. Tsapakis; K. Wolff; A.R. Winstock; P. Huezo-Diaz; C.M. Pariante; D. Hartley; D. Holt; M.L. Forsling; K.J. Aitchison (S33).

Effects of acute stress on brain-derived neurotrophic factor in the hippocampus of transgenic mouse model of depression by S. Alboni; J.M.C. Blom; D. Corsini; C. Benatti; G. Capone; C. Ferraguti; N. Barden; F. Tascedda; N. Brunello (S33-S34).

Potentiating antidepressant strategy: focus on NK1 receptor antagonists by B.P. Guiard; A.M. Gardier; P. Blier (S31-S32).

Inhibition of glycine uptake augments risperidone's effect on prefrontal glutamatergic transmission by A. Konradsson; M.M. Marcus; P. Hertel; T.H. Svensson; K.E. Jardemark (S30-S31).